Mitogens as motogens

Journal of Neuro-Oncology

Volumn 35, Issue 3, 1997, Pages 249-257

  Chicoine, Michael R ^a   Silbergeld, Daniel L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Brain tumor; Cell culture; Cell locomotion; Cytokines; Glioma; Mitogens

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; EPIDERMAL GROWTH FACTOR; INTERLEUKIN 2; LAMININ; MITOGENIC AGENT; NERVE GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

CANCER CELL CULTURE; CANCER INVASION; CELL MIGRATION; CELL STRUCTURE; CHEMOTAXIS; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME IMMUNOASSAY; GLIOMA CELL; HUMAN; HUMAN CELL; MICROSCOPY; PARENCHYMA; REVIEW; TUMOR CELL; TUMOR SPHEROID;

ANIMALS; BRAIN NEOPLASMS; CELL MOVEMENT; GLIOMA; HUMANS; MITOGENS;

EID: 0030838243     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005808315821     Document Type: Review

References (72)

1. Barnard RO, Geddes JF: The incidence of multifocal cerebral gliomas. Cancer 60: 1519-1531, 1987
2. Burger PC, Vollmer RT: Histologic factors of prognostic significance in the glioblastoma multiforme. Cancer 46: 1179-1186, 1980
3. Burger PC, Vogel FS, Green SB, Strike TA: Glioblastoma multiforme and anaplastic astrocytoma: pathologic criteria and prognostic implications. Cancer 56: 1106-1111, 1985
4. Concannon JP, Kramer S, Berry R: The extent of intracranial gliomata at autopsy and its relationship to techniques used in radiation therapy of brain tumors. Amer J Radiol 84: 99-107, 1960
5. Davis L, Martin J, Goldstein SL, Ashkenazy M: A Study of 211 patients with verified glioblastoma multiforme. J Neurosurg 6: 33-44, 1949
6. EROTC Brain Tumor Study Group: Effect of CCNU on survival, rate of objective rmeission and duration of free interval in patients with malignant gliomas-final evaluation. Eur J Cancer 14: 851-856, 1978
7. Frankel SA, German WJ: Glioblastoma multiforme: review of 219 cases with regard to natural history, pathology, diagnostic methods, and treatment. J Neurosurg 15: 489-503, 1958
8. Netsky MG, August B, Fowler W: The longevity of patients with glioblastoma multiforme. J Neursurg 7: 261-269, 1950
9. Roth JG, Elvidge AR: Glioblastoma multiforme: a clinical study. J Neurosurg 17: 736-750, 1960
10. Salford LG, Brun A, Nirfalk S: Ten-year survival among patients with supratentorial astrocytomas grade III and IV. J Neurosurg 69: 506-509, 1988
11. Scanton PW, Taylor WF: Radiotherapy of intracranial astrocytomas: analysis of 417 cases treated from 1960 through 1969. Neurosurgery 5: 301-308, 1979
12. Taveras JM, Thompson HG, Pool JL: Should we treat glioblastoma multiforme. A study of survival in 425 cases. Amer J Radiol 87: 473-479, 1962
13. Nazzaro JM, Neuwelt EA: The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. J Neurosurg 73: 331-344, 1990
14. Silbergeld DL, Rostomily RC, Alvord EC: The causes of death in patients with glioblastoma is multifactorial: clinical factors and autopsy findings in 117 cases of supratentorial glioblastoma in adults. J Neuro-Oncol 1991; 10: 179-185
15. Salazar OM, Rubin P: The spread of glioblastoma multiforme as a determining factor in radiation treated volume. Int J Radiat Oncol Biol Phys 1: 627-637, 1976
16. Noble M, Murray K, Stroobant P, Waterfield MD, Riddle P: Platelet-derived growth factor promotes division and motility and inhibits premature differentiation of the oligodendrocyte/type-2 astrocyte progenitor cell. Nature 333: 560-562, 1988
17. Westermark B, Nister M, Heldin C: Growth factors and oncogenes in human malignant glioma. Neurol Clinics 4 (3): 185-799, 1985
18. Saxena A, Ali IU: Increased expression of genes from growth factor signaling pathways in glioblastoma cell lines. Oncogene 7: 243-247, 1992
19. Westermark B, Magnusson A, Heldin C: Effect of epidermal growth factor on membrane motility and cell locomotion in cultures of human clonal glioma cell. J Neurosci Res 8: 491-507, 1982
20. Goustin AS, Loef EB, Shipley GD, Moses HL: Growth factors and cancer. Cancer Res 46: 1015-1029, 1986
21. DeLarco JE, Todaro GJ: Growth factors from murine sarcoma virus-transformed cells. Proc Natl Acad Sci 75: 4001-4005, 1978
22. Bondy M, Wiencke J, Wrensch M, Kyritsis AP: Genetics of primary brain tumors: a review. J Neurooncol 18: 69-81, 1994
23. Liberman TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A, Schlessinger J: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumors of glial origin. Nature 313: 144-147, 1985
24. Von Deimling A, Louis DN, Von Ammon K, Petersen I, Hoell T, Chung RY, Martuza RL, Schoenfeld DA, Yasargil MG, Wiestler OD, Seizinger BR: Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J Neurosurg 77: 295-301, 1992
25. Westphal M, Brunken M, Rohde E, Herrmann H-D: Growth factors in cultured human glioma cells: differential effects of FGF, EGF, and PDGF. Cancer Lett 38: 283-296, 1988
26. Hurtt MR, Moosy J, Donovan-Peluso Maryann, :Locker J: Amplification of epidermal growth factor in gliomas: histopathology and prognosis. J Neuropathol Exp Neurol 51: 84-90, 1992
27. Johnsson A, Heldin C, Wasteson A, Westermark B, Deuel TF, Huang JS, Seeburg H, Gray A, Ulrich A, Scrace G, Stroobant P, Waterfield MD : The c-sis gene encodes a precursor of the B chain of platelet-derived growth factor. EM-BO J 3: 921-928, 1984
28. Dorward NL, Hawkins RA, Whittle IR: Epidermal growth factor receptor activity and clinical outcome in glioblastoma multiforme. Br J Neurosurg 7: 197-200, 1993
29. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Petterson RF, Collins VP : Genes for epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51: 2164-2172, 1991
30. Mapstone TM: Expression of platelet-derived growth factor and transforming growth factor and their correlation with cellular morphology in glial tumors. J Neurosurg 75: 447-451, 1991
31. Bernstein JJ, Goldberg WJ, Laws ER, Conger D, Morreale V, Wood V, Wood LR : C6 glioma cell invasion and migration of rat brain after neural homografting: ultrastructure. Neurosurgery 26: 622-628, 1990
32. Chicoine MR, Silbergeld DL: Assessment of brain tumor cell motility in vivo and in vitro. J Neurosurg 82: 615-622, 1995
33. Chicoine MR, Silbergeld DL: Invading C6 glioma cells maintain tumorgenicity. J Neurosurg 83: 665-671, 1995D
34. DeRidder LI, Laerum OD: Invasion of rat neurogenic cell lines in embryonic chick heart fragments in vitro. JNCI 66 (4): 723-728, 1981
35. Bjerkvig R, Laerum OD, Mella O: Glioma cell interactions with fetal rat brain aggregates in vitro and with brain tissue in vivo. Cancer Res 46: 4071-4079, 1986
36. Horten BC, Basler GA, Shapiro WR: Xenograft of human malignant glial tumors into brains of nude mice. J Neuropath Exp Neurol 40 (5): 493-511, 1981
37. Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Sheitauer BW, Illig JJ: Image-based stereotactic biopsies in untreated intracranial neoplasms. J Neurosurg 66: 865-874, 1987
38. Boyden S: The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. J Exp Med 115: 453-466, 1962
39. Umezawa K, Asakura S, Jin Y, Matsuda M: Localization of vitronectin- and fibronectin-receptors on cultured glioma cells. Brain Res 659: 23-32, 1994
40. Nakano A, Tani E, Miyazaki K, Yamamoto Y, Furuyama J: Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J Neurosurg 83: 298-307, 1995
41. Bressler JP, Grotendorst GR, Levitov C, Hjelmeland LM: Chemotaxis of rat brain astrocytes to platelet derived growth factor. Brain Res 344: 249-254, 1985
42. 1. Br J Cancer 70: 199-203, 1994
43. Pedersen P, Ness GO, Engerbraaten O, Bjerkvig R, Lillehaug JR, Laerum OD: Heterogeneous response to the growth factor [EGF, PDGF(bb), TGF-α, bFGF, IL-2] on glioma spheroid growth, migration, and invasion. Int J Cancer 56: 255-261, 1994
44. Lund-Johansen M, Forsberg K, Bjerkvig R, Laerum OD: Effects of growth factors on a human glioma cell line during invasion into rat brain aggregate in culture. Acta Neuropath 84: 190-197, 1992
45. Lund-Johansen M, Engerbraaten O, BjerkvigR, Laerum O: Invasive glioma cells in tissue culture. Anticancer Res 1135-1152, 1990A
46. Lund-Johansen M, Bjerkvig R, Humphrey PA, Bigner SH, Laerum O : Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro. Cancer Res 50 (18): 6039-6044, 1990B
47. Terzis AJA, Arnold H, Laerum OD, Bjerkvig R : Interaction between human medulloblastomas and foetal rat brain aggregates in vitro. Acta Neurochir (Wien) 126: 11-16, 1994
48. Engerbraaten O, Bjerkvig R, Lund-Johansen M, Wester K, Pederson PH, Mork S, Backlund EO, Laerum OD : Interaction between human brain tumor biopsies and fetal rat brain tissue in vitro. Acta Neuropath 81: 130-140, 1990
49. Mørk S, De Ridder L, Laerum OD: Invasive pattern and phenotypic properties of malignant neurogenic rat cells in vivo and in vitro. Anticancer Res 2: 1-10, 1982
50. Mellstrom K, Hoglund A, Nister M, Heldin C, Westermark B, Lindberg U : The effect of platelet-derived growth factor on morphology and motility of human glial cells.
51. Chicoine MR, Silbergeld DL: The in vitro motility of human gliomas increases with increasing grade of malignancy. Cancer 75: 2904-2909, 1995
52. Chicoine MR, Madsen CL, Silbergeld DL: In vitro modification of human glioma cell locomotion by cytokines: EGF, FGF, PDGF, NGF, and TNFα. Neurosurgery 36: 1165-1171, 1995
53. Koochekpour S, Merzak A, Pilkington GJ: Extracellular matrix proteins inhibit proliferation, upregulate migration, and induce morphological changes in human glioma cell lines. Eur J Cancer 31A (3): 375-380, 1995A
54. Koochekpour S, Merzak A, Pilkington GJ: Growth factors and gangliosides stimulate laminin production by human glioma cells in vitro. Neurosci Lett 186: 53-56, 1995B
55. Bigner SH, Wong AJ, Mark J, Muhlbaier LH, Kinzler KW, Vogelstein B, Bigner DD: Relationship between gene amplificationa and chromosomal deviations in human malignant gliomas. Cancer Genet Cytogenet 29: 165-170, 1987
56. Bigner SH, Burger PC, Wong AJ, Werner MH, Hamilton SR, Muhlbaier LH, Vogelstein B, Bigner DD : Gene amplification in human malignant gliomas: clinical and histopathologic aspects. J Neuropath Exp Neuro 47: 191-205, 1988
57. Engerbraaten O, Bjerkvig R, Pederson PH, Laerum OD: Effects of EGF, bFGF, NGF, and PDGF(bb) on cell proliferative migratory and invasive capacities of human brain - tumor biopsies in vitro. Int J Cancer 53: 209-214, 1993
58. Rosen EM, Goldberg ID, Liu D, Setter E, Donovan MA, Bhargava M, Reiss M, Kacinski BM: Tumor necrosis factor stimulates epithelial tumor cell motility. Cancer Res 51: 5315-5321, 1991
59. Hajjar KA, Hajjar DP, Silverstein RL, Nachman RL: Tumor necrosis factor-mediated release of platelet-derived growth factor from cultured endothelial cells. J Exp Med 166: 235-245, 1987
60. Helseth E, Unsgaard G, Dalen A, Vik R: The effects of type beta transforming growth factor on proliferation and epidermal growth factor receptor expression in a human glioblastoma cell line. J Neurooncol 6 (3): 269-276, 1988
61. Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG, Vertosick FT: Response of low-passage human malignant gliomas in vitro to stimulation and selective inhibition of growth factor-mediated pathways. J Neurosurg 75: 284-293, 1991
62. Deuel T, Kimura A, Maehama S, Tong B: Platelet-derived growth factor: roles in normal and v-sis transformed cells. Cancer Surveys 4: 633-653, 1985
63. Heldin C, Westermark B, Wasteson A: Platelet-derived growth factor. Mol Cell Endocrinol 39: 169-187, 1985
64. Yaeger MJ, Koestner A, Marushige K, Marushige Y: The reverse transforming effects of nerve growth factor on five human neurogenic tumor cell lines: in vitro results. Acta Neuropath 83: 72-80, 1991
65. Yaeger MJ, Koestner A, Marushige K, Marushige Y: The use of nerve growth factor as a reverse transforming agent for the treatment of neurogenic tumors: in vitro results. Acta Neuropath 83: 624-629, 1992
66. Marushige K, Marushige Y, Koestner A: Growth inhibition of anaplastic glioma cells by nerve growth factor. Anticancer Res 12: 2069-2074, 1992
67. Spoerri PE, Romanello S, Petrelli L, Negro A, Guidolin D, Skaper SD : Neurotrophin-3 upregulates NGF receptors in a central nervous system glial cell line. Neuro Rep 4: 33-36, 1993
68. Kunwar S, Pai LH, Pai I: Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma cells. J Neurosurg 79: 569-576, 1993
69. Winter WE, Buck RH, Varga-House DA: Class I and Class II major histocompatibility complex molecules. In: Phillips MI (ed.) Neuroimmunology, Vol. 24. Academic Press, 1995
70. Sawamura Y, De Tribolet N: Immunobiology of brain tumors and implications for immunotherapy. In: Kaye AH, Laws ER (eds) Brain Tumors. Churchill Livingstone, New York, 1995
71. Nister M, Heldin C, Westermark B: Clonal variation in the production of a platelet-derived growth factor-like protein and expression of corresponding receptors in a human malignant glioma. Cancer Res 46: 332-340, 1986
72. Young HF, Merchant RE, Apuzzo MLJ: Immunocompetence of patients with malignant glioma. In: Salcman M (ed.) Concepts in Neurosurgery, Vol. 4: Neurobiology of brain tumors. Williams and Wilkins, Baltimore, 1993.